# 1st Quarter of Fiscal 2019 Supplementary Materials 

## Table of Contents

## Consolidated Basis

Statements of Income (Actual and Forecast) ..... 1 P
Sales Results and Plan by Product Line ..... 2 P
SG\&A and Other Income/Expenses (Actual and Forecast) ..... 3 P
Major Changes on Blance Sheets ..... $3 P$
Statements of Cash Flows ..... $4 P$
Non-Consolidated Basis
Statements of Income (Actual and Forecast) ..... 5 P
(Notes Concerning Forward-Looking Statements)
Projections throughout these materials are provided as areference for investors. They are based on estimates andforecasts, and shall not be regarded as pledges orguarantees. They shall be used on the fullacknowledgment that actual results may naturally differfrom projections.

Fiscal 2019 Statements of Income (Actual and Forecast, Consolidated)
First Quarter
$¥$ millions, rounded down

|  | June 2019 <br> 1st Quarter Results |  | June 2018 <br> 1st Quarter Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 9,038 | 100.0 | 9,053 | 100.0 | $\triangle 15$ | 99.8 |
| Cost of Sales | 5,243 | 58.0 | 5,320 | 58.8 | $\triangle 76$ | 98.6 |
| Gross profit | 3,794 | 42.0 | 3,733 | 41.2 | 60 | 101.6 |
| SG\&A expenses | 2,459 | 27.2 | 2,485 | 27.4 | $\triangle 25$ | 99.0 |
| Operating income | 1,335 | 14.8 | 1,248 | 13.8 | 86 | 106.9 |
| Other income | 69 |  | 47 |  | 21 |  |
| Other expenses | 3 |  | 24 |  | $\triangle 21$ |  |
| Ordinary income | 1,401 | 15.5 | 1,272 | 14.1 | 129 | 110.2 |
| Extraordinary income | - |  | - |  | - |  |
| Extraordinary expenses | 0 |  | 0 |  | 0 |  |
| Income berore income taxes and minority interests | 1,401 | 15.5 | 1,272 | 14.1 | 129 | 110.1 |
| Corporation tax, etc. | 422 |  | 373 |  | 49 | 113.2 |
| (Tax burden) | 30.2\% |  | 29.3\% |  |  |  |
| Minority interests | $\triangle 7$ |  | 0 |  | $\triangle 7$ |  |
| Net income | 986 | 10.9 | 898 | 9.9 | 87 | 109.7 |
| EPS (total shares) | $¥ 30.17$ |  | $¥ 27.50$ |  |  |  |
| EPS (minus treasury shares) | $¥ 32.66$ |  | $¥ 28.89$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury | 30,191,789 |  | 31,106,952 |  |  |  |

## Second Quarter

$¥$ millions, rounded down

|  | Sept. 2019 Plan |  | Sept. 2018 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 9,661 | 100.0 | 9,184 | 100.0 | 477 | 105.2 |
| Cost of Sales | 5,686 | 58.9 | 5,413 | 58.9 | 273 | 105.0 |
| Gross profit | 3,975 | 41.1 | 3,771 | 41.1 | 204 | 105.4 |
| SG\&A expenses | 2,830 | 29.3 | 2,579 | 28.1 | 251 | 109.7 |
| Operating income | 1,144 | 11.8 | 1,192 | 13.0 | $\triangle 47$ | 96.0 |
| Other income | 20 |  | 75 |  | $\triangle 55$ |  |
| Other expenses | $\triangle 3$ |  | 59 |  | $\triangle 62$ |  |
| Ordinary income | 1,168 | 12.1 | 1,208 | 13.2 | $\triangle 39$ | 96.7 |
| Extraordinary income | 1,990 |  | 3,998 |  | $\triangle 2,008$ |  |
| Extraordinary expenses | $\triangle 0$ |  | 1 |  | $\triangle 1$ |  |
| Income before income taxes and minority interests | 3,158 | 32.7 | 5,205 | 56.7 | $\triangle 2,046$ | 60.7 |
| Corporation tax, etc. | 987 |  | 1,569 |  | $\triangle 582$ |  |
| (Tax burden) | 31.3\% |  | 30.2\% |  |  |  |
| Minority interests | 0 |  | 0 |  | $\triangle 22$ |  |
| Net income | 2,193 | 22.7 | 3,635 | 39.6 | $\triangle 1,441$ | 60.3 |

## First Half

$\nexists$ millions, rounded down

|  | Sept. 2019 <br> Interim Plan |  | Sept. 2018 Results |  | Year-on-Year Comparison |  | Sept. 2019 <br> Initial Plan |  | Initial Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 18,700 | 100.0 | 18,238 | 100.0 | 461 | 102.5 | 18,700 | 100.0 | - | 100.0 |
| Cost of Sales | 10,930 | 58.4 | 10,733 | 58.8 | 196 | 101.8 | 10,930 | 58.4 | - | 100.0 |
| Gross profft | 7,770 | 41.6 | 7,505 | 41.2 | 264 | 103.5 | 7,770 | 41.6 |  | 100.0 |
| SG\&A expenses | 5,290 | 28.3 | 5,064 | 27.8 | 225 | 104.5 | 5,290 | 28.3 | - | 100.0 |
| Operating income | 2,480 | 13.3 | 2,440 | 13.4 | 39 | 101.6 | 2,480 | 13.3 | - | 100.0 |
| Other income | 90 |  | 123 |  | $\triangle 33$ |  | 90 |  | - |  |
| Other expenses | - |  | 83 |  | $\triangle 83$ |  | - |  | - |  |
| Ordinary income | 2,570 | 13.7 | 2,480 | 13.6 | 89 | 103.6 | 2,570 | 13.7 | - | 100.0 |
| Extraordinary income | 1,990 |  | 3,998 |  | $\triangle 2,008$ |  | 1,990 |  | - |  |
| Extraordinary expenses | - |  | 1 |  | $\triangle 1$ |  | - |  | - |  |
| Income berore income taxes and minority interests | 4,560 | 24.4 | 6,477 | 35.5 | $\triangle 1,917$ | 70.4 | 4,560 | 24.4 | - | 100.0 |
| Corporation tax, etc. | 1,410 |  | 1,942 |  | $\triangle 532$ |  | 1,410 |  | - |  |
| (Tax burden) | 30.9\% |  | 30.0\% |  |  |  | 30.9\% |  |  |  |
| Minority interests | $\triangle 30$ |  | 0 |  | $\triangle 30$ |  | $\triangle 30$ |  | - |  |
| Net income | 3,180 | 17.0 | 4,534 | 24.9 | $\triangle 1,354$ | 70.1 | 3,180 | 17.0 | - | 100.0 |
| EPS (total shares) | $¥ 97.30$ |  | $¥ 138.74$ |  | - |  | ¥97.30 |  |  |  |
| EPS (minus treasury shares) | $¥ 105.31$ |  | $¥ 147.41$ |  |  |  | $¥ 105.31$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury | 30,195,238 |  | 30,760,964 |  |  |  | 30,195,238 |  |  |  |

Fiscal 2019 Sales Results and Plan by Product Line (Consolidated)
First Quarter $\quad \neq$ millions, rounded down

|  | June 2019 <br> 1st Quarter Results |  | June 2018 <br> 1st Quarter Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 854 | 9.5\% | 842 | 9.3\% | 12 | 101.5\% |
| Surgical products | 7,947 | 87.9\% | 7,947 | 87.8\% | 0 | 100.0\% |
| Treatment products | 44 | 0.5\% | 49 | 0.5\% | $\triangle 4$ | 89.9\% |
| Others | 191 | 2.1\% | 214 | 2.4\% | $\triangle 23$ | 89.0\% |
| Total | 9,038 | 100.0\% | 9,053 | 100.0\% | $\triangle 15$ | 99.8\% |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 2,146 | 23.7\% | 2,248 | 24.8\% | $\triangle 102$ | 95.5\% |
| Other non-woven product | 292 | 3.2\% | 311 | 3.4\% | $\triangle 19$ | 93.8\% |
| Kit products | 5,481 | 60.7\% | 5,339 | 59.0\% | 142 | 102.7\% |
| Steel instruments | 27 | 0.3\% | 48 | 0.5\% | $\triangle 21$ | 56.1\% |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 52 |  | 69 |  | $\triangle 17$ |  |
| Others | 23 |  | 21 |  | 2 |  |

Second Quarter $\quad \neq$ millions, rounded down

|  | Sept. 2019 <br> Plan |  | Sept. 2018 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 847 | 8.8\% | 898 | 9.8\% | $\triangle 50$ | 94.3\% |
| Surgical products | 8,532 | 88.3\% | 8,024 | 87.4\% | 507 | 106.3\% |
| Treatment products | 50 | 0.5\% | 46 | 0.5\% | 4 | 109.0\% |
| Others | 231 | 2.4\% | 215 | 2.4\% | 16 | 107.4\% |
| Total | 9,661 | 100.0\% | 9,184 | 100.0\% | 477 | 105.2\% |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 2,203 | 22.8\% | 2,219 | 24.2\% | $\triangle 15$ | 99.3\% |
| Other non-woven product | 287 | 3.0\% | 308 | 3.4\% | $\triangle 21$ | 93.1\% |
| Kit products | 5,918 | 61.3\% | 5,462 | 59.5\% | 455 | 108.3\% |
| Steel instruments | 122 | 1.3\% | 34 | 0.4\% | 88 | 358.7\% |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 87 |  | 68 |  | 18 |  |
| Others | 16 |  | 18 |  | $\triangle 2$ |  |

First Half
$¥$ millions, rounded down

|  | Sept. 2019 <br> Interim Plan |  | Sept. 2018 Results |  | Year-on-Year <br> Comparison |  | Sept. 2019 <br> Initial Plan |  | Initial Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Sterilization products | 1,702 | 9.1\% | 1,740 | 9.5\% | $\triangle 38$ | 97.8\% | 1,702 | 9.1\% |  | 100.0\% |
| Surgical products | 16,480 | 88.1\% | 15,972 | 87.6\% | 507 | 103.2\% | 16,480 | 88.1\% |  | 100.0\% |
| Treatment products | 94 | 0.5\% | 95 | 0.5\% | $\triangle 0$ | 99.2\% | 94 | 0.5\% | - | 100.0\% |
| Others | 423 | 2.3\% | 430 | 2.4\% | $\triangle 7$ | 98.3\% | 423 | 2.3\% | - | 100.0\% |
| Total | 18,700 | 100.0\% | 18,238 | 100.0\% | 461 | 102.5\% | 18,700 | 100.0\% |  | 100.0\% |
| Itemized surgical products |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 4,350 | 23.3\% | 4,467 | 24.5\% | $\triangle 117$ | 97.4\% | 4,350 | 23.3\% |  | 100.0\% |
| Other non-woven product | 580 | 3.1\% | 620 | 3.4\% | $\triangle 40$ | 93.4\% | 580 | 3.1\% | - | 100.0\% |
| Kit products | 11,400 | 61.0\% | 10,801 | 59.2\% | 598 | 105.5\% | 11,400 | 61.0\% | - | 100.0\% |
| Steel instruments | 150 | 0.8\% | 82 | 0.5\% | 67 | 180.8\% | 150 | 0.8\% | - | 100.0\% |
| Itemized external sales by subsidiary |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 140 |  | 138 |  | 1 |  | 140 |  | - |  |
| Others | 40 |  | 40 |  | $\triangle 0$ |  | 40 |  | - |  |

Sales Composition by Kit Treatment Category


SG\&A and Other Income / Expenses (Actual and Forecast, Consolidated)

SG\&A Expenses
$¥$ millions, rounded down

|  | June 2019 <br> 1st Quarter Results | June 2018 <br> 1st Quarter Results | Year-on-Year Comparison |
| :---: | :---: | :---: | :---: |
| Packaging and transportation | 256 | 258 | $\triangle 2$ |
| Samples | 134 | 230 | $\triangle 95$ |
| Advertising | 8 | 11 | $\triangle 2$ |
| Personnel | 953 | 973 | $\triangle 19$ |
| Travel | 150 | 153 | $\triangle 3$ |
| Communication | 33 | 34 | $\triangle 1$ |
| Consumables | 21 | 22 | $\triangle 1$ |
| Taxes and public charges | 81 | 82 | $\triangle 1$ |
| Depreciation | 260 | 224 | 35 |
| Testing and research | 152 | 138 | 13 |
| Land and housing rent | 110 | 107 | 2 |
| Miscellaneous | 143 | 96 | 47 |
| Others | 154 | 152 | 2 |
| Total | 2,459 | 2,485 | $\triangle 25$ |

Other Income/Expenses $\quad \neq$ millions, rounded down

|  | June 2019 <br> 1st Quarter Results | June 2018 <br> 1st Quarter Results | Year-on-Year <br> Comparison |
| :--- | ---: | ---: | ---: |
| Interest received | 15 | 9 | 5 |
| Dividend received | 38 | 29 | 8 |
| (Total financial earnings) | 53 | 38 | 14 |
| Foreign exchange gain | 6 | - | 6 |
| Miscellaneous income | 10 | 9 | 1 |
| Total Other income | 69 | 47 | 21 |
| Foreign exchange loss | - | 10 | $\Delta 10$ |
| Miscellaneous losses | 3 | 13 | $\triangle 10$ |
| Total non-operating expenses | 3 | 24 | $\Delta 21$ |

## Major Changes on Balance Sheets / Statements of Cash Flows (Consolidated)

| Major Changes on Balance Sheets |  |  |  | $\ddagger$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \hline \hline \text { Balance at June 30, } \\ 2019 \end{gathered}$ | Change |  | Balance at June 30, 2019 | Change |
| Current assets | 44,936 | 827 | Current liabilities | 10,812 | 1,624 |
| Cash and bank deposits | 24,054 | 717 | Notes and accounts payable | 4,362 | $\triangle 222$ |
| Notes and accounts receivable | 12,313 | 308 | Accrued expenses | 2,830 | 1,879 |
| Short-term investments | - |  | Long-term loans due within 1 year | - |  |
| Inventories | 7,993 | $\triangle 296$ | Income taxes | 416 | $\triangle 978$ |
| Others | 574 | 97 | Allowance for employees' bonuses | 164 | $\triangle 322$ |
|  |  |  | Payable notes for equipment | 1,684 | 331 |
|  |  |  | Reserve for disaster loss | - |  |
|  |  |  | Others | 1,353 | 936 |
| Fixed assets | 61,064 | 1,845 | Long-term liabilities | 2,897 | 163 |
| Property, plant and equipment |  |  | Others | 285 |  |
| Property, plant and equipment | 47,946 | 2,001 | Others | 2,611 | 163 |
| Buildings and structures | 22,610 | $\triangle 291$ | Total liabilities | 13,709 | 1,787 |
| Machinery, equipment and vehi | 10,588 | $\triangle 578$ | Total net assets | 92,290 | 885 |
| Land | 9,610 | 0 | Common stock | 7,123 |  |
| Construction in progress | 3,846 | 2,924 | Capital surplus | 8,336 | - |
| Others | 1,289 | $\triangle 51$ | Retained earnings | 80,190 | 419 |
| Intangibles | 2,483 | $\triangle 116$ | Treasury stock | $\triangle 8,645$ | 17 |
| Investments and others | 10,634 | $\triangle 39$ | Others | 5,286 | 448 |
| Investments securities | 9,445 | 662 |  |  |  |
| Others | 1,188 | $\triangle 701$ |  |  |  |
| Total assets | 106,000 | 2,673 | Total liabilities and shareholders' equity | 106,000 | 2,673 |

Equity ratio increased from $88.5 \%$ at the end of the previous fiscal year to $86.9 \%$.

## Statements of Cash Flows

$¥$ millions, rounded down

| I Operating activities | 1,767 | Income before income taxes and minority interests Depreciation expenses Income taxes paid | $\begin{array}{r} 1,401 \\ 1,289 \\ \triangle 1,348 \end{array}$ |
| :---: | :---: | :---: | :---: |
| II Investing activities | $\triangle 1,181$ | Purchase of tangible fixed assets Purchase of intangible fixed assets | $\begin{array}{r} \triangle 1,025 \\ \triangle 105 \end{array}$ |
| IIIFinancing activities | $\triangle 466$ | Cash dividends paid | $\triangle 484$ |
| IVEffect of exchange rate changes | 13 |  |  |
| Net changes in cash and cash equivalents | 133 |  |  |

Fiscal 2019 Statements of Income (Actual and Forecast, Non-Consolidated)
First Quarter
$¥$ millions, rounded down

|  | June 2019 <br> 1st Quarter Results |  | June 2018 <br> 1st Quarter Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,964 | 100.0 | 8,962 | 100.0 | 2 | 100.0 |
| Cost of Sales | 5,400 | 60.2 | 5,459 | 60.9 | $\triangle 59$ | 98.9 |
| Gross profit | 3,564 | 39.8 | 3,503 | 39.1 | 61 | 101.8 |
| SG\&A expenses | 2,404 | 26.8 | 2,463 | 27.5 | $\triangle 58$ | 97.6 |
| Operating income | 1,159 | 12.9 | 1,039 | 11.6 | 120 | 111.5 |
| Other income | 64 |  | 42 |  | 21 |  |
| Other expenses | 9 |  | 31 |  | $\triangle 21$ |  |
| Ordinary income | 1,214 | 13.5 | 1,051 | 11.7 | 163 | 115.5 |
| Extraordinary income | - |  | - |  |  |  |
| Extraordinary expenses | 0 |  | 0 |  | 0 |  |
| Income before income taxes and minority interests | 1,214 | 13.5 | 1,051 | 11.7 | 163 | 115.5 |
| Corporation tax, etc. | 370 |  | 320 |  | 49 |  |
| (Tax burden) | 30.5\% |  | 30.5\% |  |  |  |
| Net income | 843 | 9.4 | 730 | 8.2 | 113 | 115.5 |
| EPS (total shares) | 25.82 |  | 22.36 |  |  |  |
| EPS (minus treasury shares) | 27.95 |  | 23.49 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,191,789 |  | 31,106,952 |  |  |  |

Second Quarter $\quad ¥$ millions, rounded down

|  | Sept. 2019 Plan |  | Sept. 2018 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 9,555 | 100.0 | 9,097 | 100.0 | 457 | 105.0 |
| Cost of Sales | 5,689 | 59.5 | 5,586 | 61.4 | 102 | 101.8 |
| Gross profit | 3,865 | 40.5 | 3,510 | 38.6 | 354 | 110.1 |
| SG\&A expenses | 2,705 | 28.3 | 2,557 | 28.1 | 148 | 105.8 |
| Operating income | 1,160 | 12.1 | 953 | 10.5 | 206 | 121.7 |
| Other income | 5 |  | 59 |  | $\triangle 53$ |  |
| Other expenses | 0 |  | 70 |  | $\triangle 69$ |  |
| Ordinary income | 1,165 | 12.2 | 943 | 10.4 | 222 | 123.6 |
| Extraordinary income | 1,990 |  | 3,998 |  | $\triangle 2,008$ |  |
| Extraordinary expenses | $\triangle 0$ |  | 1 |  | $\triangle 1$ |  |
| Income before income taxes and minority interests | 3,155 | 33.0 | 4,939 | 54.3 | $\triangle 1,784$ | 63.9 |
| Corporation tax, etc. | 959 |  | 1,506 |  | $\triangle 547$ |  |
| (Tax burden) | 30.4\% |  | 30.5\% |  |  |  |
| Net income | 2,196 | 23.0 | 3,433 | 37.7 | $\triangle 1,237$ | 64.0 |

First Half

|  | Sept. 2019 <br> Interim Plan |  | Sept. 2018 <br> Results |  | Year-on-Year Comparison |  | Sept. 2019 <br> Initial Plan |  | Initial Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 18,520 | 100.0 | 18,060 | 100.0 | 459 | 102.5 | 18,520 | 100.0 |  | 100.0 |
| Cost of Sales | 11,090 | 59.9 | 11,046 | 61.2 | 43 | 100.4 | 11,090 | 59.9 |  | 100.0 |
| Gross profit | 7,430 | 40.1 | 7,013 | 38.8 | 416 | 105.9 | 7,430 | 40.1 |  | 100.0 |
| SG\&A expenses | 5,110 | 27.6 | 5,020 | 27.8 | 89 | 101.8 | 5,110 | 27.6 |  | 100.0 |
| Operating income | 2,320 | 12.5 | 1,993 | 11.0 | 326 | 116.4 | 2,320 | 12.5 |  | 100.0 |
| Other income | 70 |  | 102 |  | $\triangle 32$ |  | 70 |  |  |  |
| Other expenses | 10 |  | 101 |  | $\triangle 91$ |  | 10 |  |  |  |
| Ordinary income | 2,380 | 12.9 | 1,994 | 11.0 | 385 | 119.3 | 2,380 | 12.9 |  | 100.0 |
| Extraordinary income | 1,990 |  | 3,998 |  | $\triangle 2,008$ |  | 1,990 |  |  |  |
| Extraordinary expenses | - |  | 1 |  | $\triangle 1$ |  | - |  |  |  |
| Income before income taxes and minority interests | 4,370 | 23.6 | 5,991 | 33.2 | $\triangle 1,621$ | 72.9 | 4,370 | 23.6 |  | 100.0 |
| Corporation tax, etc. | 1,330 |  | 1,827 |  | $\triangle 497$ |  | 1,330 |  |  |  |
| (Tax burden) | 30.4\% |  | 30.5\% |  |  |  | 30.4\% |  |  |  |
| Net income | 3,040 | 16.4 | 4,163 | 23.1 | $\triangle 1,123$ | 73.0 | 3,040 | 16.4 |  | 100.0 |
| EPS (total shares) | 93.02 |  | 127.41 |  |  |  | 93.02 |  |  |  |
| EPS (minus treasury shares) | 100.68 |  | 135.36 |  |  |  | 100.68 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Average number of shares outstanding (after deducting treasury shares) | 30,195,238 |  | 30,760,964 |  |  |  | 30,195,238 |  |  |  |

